Search Within

Tala Shekarkhand

Formats
  1. Meeting Abstract (32)
  2. Journal Article (6)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (40)
  2. Center for Hematologic Malignancies (39)
  3. Department of Medicine (39)
  4. Hematologic Malignancies Research (39)
  5. Myeloma (39)
  6. CTCR Scholars (38)

More Groups

People
  1. Alexander Lesokhin (39)
  2. Carlyn Rose Tan (38)
  3. Hani Hassoun (38)
  4. Malin Hultcrantz (38)
  5. Sham Mailankody (38)
  6. Urvi Shah (38)

More People

Years
  1. 2024 (20)
  2. 2023 (13)
  3. 2022 (3)
  4. 2021 (1)
  5. 2020 (2)
  6. 2019 (1)
Publications
  1. Blood (19)
  2. Clinical Lymphoma, Myeloma and Leukemia (12)
  3. Blood Advances (2)
  4. Blood Cancer Journal (2)
  5. Journal of Clinical Oncology (2)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. Elsevier Inc. (12)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real world experience of talquetamab in relapsed refractory myeloma, first report from the IMWG Consortium
    Meeting Abstract

    Janakiram, M.; Tan, C.; Popat, R.; Kastritis, E.; Martínez-Lopez, J.; Shekarkhand, T.; Bansal, R.; De Menezes Silva Corraes, A.; de la puerta, M. C.; Sáez Marín, A. J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • CMV reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R.; Miller, K.; Costa, B.; Rajeeve, S.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Tan, C.; Shekarkhand, T.; Firestone, R.; Jurgens, E.; Miller, K.; Lesokhin, A.; Shah, G.; Korde, N.; Rajeeve, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Rueda, C.; Shekarkhand, T.; Derkach, A.; Korde, N.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
    Journal Article

    Firestone, R. S.; Socci, N. D.; Shekarkhand, T.; Zhu, M.; Qin, W. G.; Hultcrantz, M.; Mailankody, S.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Journal Article

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M. L.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
    Journal Article

    Nath, K.; Shekarkhand, T.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Nishimura, N.; Farzana, T.; Rueda, C.; Chung, D. J.; Landau, H. J.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
    Journal Article

    Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save